{'fraction_non_alphanumeric': 0.0288, 'fraction_numerical': 0.0016, 'mean_word_length': 6.364705882352941, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Some newer antimicrobial agents with antipseudomonal activity

Several new antimicrobial agents have been released in Australia which exhibit clinically-useful activity against Pseudomonas aeruginosa. Two of these, the quinolones norfloxacin and ciprofloxacin, are administered by mouth. The other three agents, ceftazidime, aztreonam and imipenem, are parenterally-administered fJ-Iactam agents. Criteria for the antimicrobial susceptibility testing of all these agents have been published for the National Committee for Clinical Laboratory Standards (Kirby-Bauer)' and the calibrated dichotomous sensitivity (CDS)2 methods.